Glypinamide

This classification denotes an anti-diabetic agent with the molecular formula C13H18ClN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) ORE084U8IP, chemically known as urea, 1-((p-chlorophenyl)sulfonyl)-3-(hexahydro-1h-azepin-1-yl)- but more generally known as glypinamide, which bears US NIH Compound Identifier 219111. European Medicines Agency schedules Glypinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07956MIG. The term GLYPINAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). GLYPINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glypinamide under HS 29350090 and SITC 51580. As of Q4 2014, GLYPINAMIDE remains US FDA's Preferred Term for this commodity. Glypinamide bears US NLM identifiers UMLS ID C1880993 and NCI Concept Code C65811. SMILES: CLC1CCC(S(=O)(=O)NC(=O)NN2CCCCCC2)CC1.